Dana dhuwit saben siji saham Gracell (GRCL)

Simbol lan logo merek Gracell (GRCL)

Risks of dependence on external partnerships during the implementation of FasTCAR are mitigated as the current cash per share demonstrates resilience; the value of 2.42 reflects this status. The acquisition by the behemoth AstraZeneca and the potential of CAR-T therapy create a powerful growth catalyst for Gracell Biotechnologies (GRCL). Stable management, integrated into the corporate structure, guarantees full funding for the accelerated market launch of the drugs.

GRCL Gracell Bio: Dhuwit awis saben siji saham ing interval 04.07.2022 - 03.03.2024

Rincian metrik komprehensif lan analitis Gracell Biotechnologies Inc. (GRCL)

- rega pasar lan target rega analis:
- data dhuwit lan arus kas:
Ringkesan analisis perusahaan:GRCL (Gracell)
Produk dadi gracellbio.com

The development of the FasTCAR platform enables Gracell Biotechnologies (GRCL) to effectively monetize cell technologies. The cash per share trend reflects the rate of change in the issuer's liquid reserves. This metric is calculated by dividing the total amount of cash by the total number of outstanding securities. This indicator determines the actual size of the "safety cushion" available to each shareholder. A high level of liquidity confirms the financial stability of the biotechnology business.